相关实验视频
Updated: Jul 23, 2025

09:53
In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge
Published on: June 15, 2018
7.5K
miR-33缺乏对代谢和心血管疾病的影响:对治疗干预的影响
Rebeca Ortega1, Bo Liu1, Shanta J Persaud1
1Department of Diabetes, School of Cardiovascular and Metabolic Medicine & Sciences, King's College London, Guy's Campus, London SE1 1UL, UK.
International journal of molecular sciences
|July 14, 2023
概括
微RNAs (miRNAs),特别是miR-33,调节脂质和葡萄糖代谢. 抑制miR-33可能为代谢和心血管疾病 (如失脂症和动脉样硬化) 提供治疗策略.
科学领域:
- 分子生物学分子生物学
- 遗传学 遗传学 是一个
- 生物化学 生物化学
背景情况:
- 微RNA (miRNA) 是小型非编码RNA,在转录后调节基因表达.
- miRNAs与炎症,细胞生长和能量代谢有关.
- miR-33在脂质和葡萄糖代谢中起作用,影响代谢和心血管健康.
研究的目的:
- 审查miR-33在代谢和心血管疾病中的作用.
- 讨论miR-33在脂质和葡萄糖代谢调节中的参与.
- 评估miR-33缺乏作为一种潜在的治疗策略.
主要方法:
- 关于miR-33和代谢/心血管疾病的研究文献综述.
- 对miR-33涉及SREBP-1和SREBP-2的监管机制的分析.
- 讨论miR-33抑制的治疗影响.
主要成果:
- miR-33是脂质生物合成和胆固醇排放的关键调节剂.
- miR-33的失调与脂质不良症,NAFLD,肥胖,糖尿病,动脉样硬化和AAA有关.
- miR-33位于编码SREBP-1和SREBP-2的基因内.
结论:
- miR-33是代谢和心血管疾病发病的一个重要因素.
- 针对miR-33为这些疾病提供了一个有前途的治疗途径.
- 进一步研究miR-33缺乏症作为治疗方法是有必要的.
相关概念视频
Mitral Regurgitation III: Medical Management
19
Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
19
MicroRNAs
3.0K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
Atherosclerosis III: Management
13
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
13

